Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023

Related Keywords

Australia ,United Kingdom ,Hong Kong ,Osaka ,Japan ,United States ,Belgium ,Cairo ,Al Qahirah ,Egypt ,China ,British ,Belgian ,Japanese ,American ,Annie Cheng ,Michael Shi ,Mark Lee ,Sara Noonan ,Jun Saito ,Awny Farajallah ,Ahcene Djaballah ,Jemma Nash ,Gastroenterol Hepatol ,Ben Atwell Alex Shaw ,Zhou Yi ,International Agency For Research On Cancer ,Nasdaq ,Linkedin ,Solebury Strategic Communications ,Drug Administration ,Journal Of The American Medical Association ,Global Medical Affairs Oncology At Takeda ,China Limited Nasdaq ,European Society For Medical Oncology ,Exchange Commission ,Stock Exchange Of Hong Kong ,Takeda Pharmaceutical Company Limited ,International Media ,Clinical Cancer Research ,Prescription Drug User Fee Act ,Target Action Date Set ,Results From ,New Drug Application ,Global Medical Affairs Oncology ,Chief Medical Officer ,American Medical Association ,European Society ,Medical Oncology ,International Agency ,Annual Report ,Securities Litigation Reform Act ,Stock Exchange ,Cancer Res ,Cancer Biol ,Overall Survival ,Cancer Statistics ,Mortality Worldwide ,Rev Gastroenterol Hepatol ,Colorectal Cancer ,Winding Road From Negative Predictive Factor ,Positive Actionable ,Media Contacts ,Senior Vice President ,Vice President ,Brad Miles ,Ben Atwell ,Alex Shaw ,